BeiGene, Ltd. (NASDAQ:BGNE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $247.07.

A number of research analysts have commented on BGNE shares. Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. StockNews.com lowered shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities started coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price for the company. TD Cowen increased their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. boosted their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd.

BeiGene Stock Up 4.3 %

Shares of NASDAQ:BGNE opened at $215.00 on Friday. The business’s 50 day moving average is $212.42 and its 200 day moving average is $184.46. The stock has a market cap of $20.94 billion, a P/E ratio of -26.09 and a beta of 0.63. BeiGene has a 52-week low of $126.97 and a 52-week high of $248.16. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 EPS. Sell-side analysts predict that BeiGene will post -5.38 EPS for the current year.

Insider Activity at BeiGene

In other news, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. Insiders have sold 63,538 shares of company stock valued at $12,594,017 in the last ninety days. Corporate insiders own 7.43% of the company’s stock.

Institutional Trading of BeiGene

Large investors have recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in BeiGene during the 3rd quarter worth approximately $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BeiGene during the 3rd quarter valued at approximately $67,000. SG Americas Securities LLC purchased a new stake in shares of BeiGene in the 3rd quarter valued at $105,000. Finally, PFG Investments LLC acquired a new stake in shares of BeiGene in the third quarter worth $210,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.